Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Feb 2022
Price :
$35
*
At a glance
- Drugs Naltrexone/bupropion (Primary)
- Indications Obesity
- Focus Adverse reactions; Registrational
- Acronyms LIGHT; Light Study
- Sponsors Orexigen Therapeutics [CEASED]; Takeda
- 15 Jun 2021 Results of post-hoc analysis assessing safety and efficacy of NB and placebo among individuals with overweight or obesity who were also taking antidepressant therapy during the LIGHT trial, published in the Journal of Affective Disorders
- 04 Sep 2020 Results of post hoc analysis of data from the 6 naltrexone ER/bupropion ER trials assessing the percent of subjects achieving a weight loss of 5% to 10%, 10% to 15%, and more than 15% at weeks 16, 52, 104, and 208 presented at the 2020 European and International Congress on Obesity
- 20 May 2017 Results assessing the effect of Naltrexone/Buproplon on body weight of overweight and obese participants with elevated cardiovascular risk, presented at the 24th European Congress on Obesity.